Logo

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Share this

Tanvex Reports Results of TX05 (biosimilar- trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Shots:

  • The P-III study evaluates the efficacy and safety of TX05 vs Herceptin (trastuzumab) in patients with human epidermal growth factor receptor 2-positive early breast cancer
  • The 1EPs was an assessment of pCR following neoadjuvant therapy and definitive surgery in the per-protocol population
  • Results: Patients achieved pCR (48.8% vs 45.3%) in the per-protocol population

 ­ Ref: Tanvex  | Image: Tanvex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions